Novo Nordisk Pharmatech highlighting its cGMP FEF® Quats at CPhI Madrid
News | Novo Nordisk Pharmatech A/S
SEPTEMBER 25, 2018
Novo Nordisk Pharmatech, will exhibit at October’s landmark CPhI Worldwide expo in Madrid to highlight the versatility of its FEF® Quats across a wide range of applications.
With more than 65 years’ experience of Quats production, Novo Nordisk Pharmatech industry is able to deliver unsurpassed levels of purity and quality. Its cGMP manufactured pharmaceutical grade Quats comply with ICH Q7, including validated processes, complete traceability and complete documentation.
Versatile FEF® Quats
These properties make Novo Nordisk Pharmatech FEF® Quats particularly suited for pharmaceutical applications, as preservatives or APIs in many ophthalmic, nasal, oral and topical drugs and in a variety of solutions, ointments and creams. They can also be used as lysing or precipit, as well as useful across the cosmetic industry as conditioning, emulsifying and preserving agents.
At the Novo Nordisk Pharmatech stand at 8A20 in Hall 8 of Madrid’s IFEMA, a team led by Technical Sales Manager Henrik Ammitzbøll will be displaying a wide range of quats products, including Benzalkonium Chloride, Cetrimide, Cetrimonium Bromide (CTAB) and Strong Cetrimide for pharma applications such as ophthalmic, nasal, topical and oral applications as antimicrobial excipients.
“This will be an important stand to visit for decision makers purchasing for raw materials or involved in product development or quality assurance,” said Henrik Ammitzbøll.
“We will be able to show that we can deliver very high product quality and full regulatory compliance,” he added.
About Novo Nordisk Pharmatech
Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, and now part of the Novo Nordisk pharmaceutical group since its acquisition in 1986. On September1, 2015, the company became Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.
All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.
For Financial Year 2016, Novo Nordisk Pharmatech reported world sales totalling 669 million Danish kroner (DEK) with more than half of all sales recorded in North America.
About CPhI Worldwide 2018
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators and gain insights on latest industry trends.
Now in its 29th year, the 2018 event is a three-day event opening October 9 at IFEMA, Feria de Madrid, Spain, which last hosted the event in 2015. CPhI Worldwide 2018. CPhI Worldwide includes the co-located zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment and InnoPack pharmaceutical packaging events. Together, they are expected to attract a record 45,000 delegates along with 2,500 exhibiting companies from 153 countries.
New for 2018, the Expo will feature bioLIVE, a new specialized exhibition focusing on the biopharmaceutical industry.
The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: https://www.cphi.com/europe/.
Vanessa León, Marketing Manager, Novo Nordisk Pharmatech A/S
Tel:+45 404 262 84
Click on Novo Nordisk Pharmatech at CPhI, Madrid for more information.
Click on Novo Nordisk Pharmatech to contact the company directly.
Click on Novo Nordisk Pharmatech at CPhI Worldwide 2018 for further information.